IDH1 and acute myeloid leukemia: Recent development of epigenetic differentiation therapy for IDH1 mutated and IDH2 mutated AML with ivosidenib and enasidenib, respectively, has reinvigorated such approaches for other molecular subtypes of AML11,12.